I am a neuroscientist employing strategies of biochemistry, pathology, pharmacology and developmental biology to examine the mechanisms of neuronal injury contributing to degenerative conditions. My major long-term interest has been excitotoxicity and rec
The majority of stroke results from focal brain infarction, followed by substantial secondary excitotoxic damage in the surrounding areas. Tau has been shown to contribute to excitotoxicity and neurodegeneration in mouse models of Alzheimer’s disease (AD). Preliminary data show that tau reduction also protects against excitotoxic damage after experimental stroke. We aim to dissect the molecular mechanisms of stroke using a tau-deficient mouse model.
Interaction Of Amyloid-beta And Tau Pathology In Alzheimer's Disease
Funder
National Health and Medical Research Council
Funding Amount
$122,592.00
Summary
Currently, over 200,000 Australians are affected by Alzheimer's disease (AD) and related forms of dementia, causing a huge socio-economic damage. To overcome the lack of effective treatments, we need to understand the underlying causes and translate them into therapy. Using state-of-the-art cell culture and genetic mouse models, I will reveal fundamental processes in AD and related dementias, and develop tailored treatments to battle these devastating disorders.
Parkinson's Disease (PD) is one of the most common neurodegenerative disorders. Its incidence increases steadily with age affecting approximately 1% of the population at age 65 and up to 5% by the age of 85. At the time of diagnosis, patients suffer from a range of motor impairments that worsen over time. Pathologically these patients are characterised by the accumulation of a protein known as alpha-synuclein in specific types of nerve cells in their brain. However, the function of this protein ....Parkinson's Disease (PD) is one of the most common neurodegenerative disorders. Its incidence increases steadily with age affecting approximately 1% of the population at age 65 and up to 5% by the age of 85. At the time of diagnosis, patients suffer from a range of motor impairments that worsen over time. Pathologically these patients are characterised by the accumulation of a protein known as alpha-synuclein in specific types of nerve cells in their brain. However, the function of this protein is unknown. This proposal will clarify the role of alpha-synuclein in PD and normal CNS function and provide new potential therapeutic targets for the treatment of PD and other neurodegenerative disorders in which oxidative stress, excitotoxicity and central nervous system trauma have been implicated.Read moreRead less
My research focuses on understanding pathobiological mechanisms in acute and chronic neurodegenerative conditions such as stroke and Parkinson’s disease which have large burdens on the community through health care costs and on families because of the lack of effective treatments. An improved understanding of how brain cells die and of how the most abundant brain cell, the astrocyte, can be engineered to be a resource for regenerative medicine offer promise for improved clinical management.